<?xml version="1.0" encoding="UTF-8"?>
<!DOCTYPE article PUBLIC "-//NLM//DTD JATS (Z39.96) Journal Publishing DTD v1.3 20210610//EN" "JATS-journalpublishing1-3.dtd">
<article article-type="research-article" dtd-version="1.3" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xml:lang="ru"><front><journal-meta><journal-id journal-id-type="publisher-id">tiblj</journal-id><journal-title-group><journal-title xml:lang="ru">Туберкулез и болезни легких</journal-title><trans-title-group xml:lang="en"><trans-title>Tuberculosis and Lung Diseases</trans-title></trans-title-group></journal-title-group><issn pub-type="ppub">2075-1230</issn><issn pub-type="epub">2542-1506</issn><publisher><publisher-name>Медицинские знания и технологии</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="doi">10.21292/2075-1230-2021-99-12-14-21</article-id><article-id custom-type="elpub" pub-id-type="custom">tiblj-1593</article-id><article-categories><subj-group subj-group-type="heading"><subject>Research Article</subject></subj-group><subj-group subj-group-type="section-heading" xml:lang="ru"><subject>ОРИГИНАЛЬНЫЕ СТАТЬИ</subject></subj-group><subj-group subj-group-type="section-heading" xml:lang="en"><subject>ORIGINAL ARTICLES</subject></subj-group></article-categories><title-group><article-title>Оценка эффективности массового скрининга для выявления туберкулезной инфекции у детей в возрасте от 1 до 7 лет в Москве</article-title><trans-title-group xml:lang="en"><trans-title>Evaluation of effectiveness of mass screening for tuberculosis infection in children from 1 to 7 years old in Moscow</trans-title></trans-title-group></title-group><contrib-group><contrib contrib-type="author" corresp="yes"><contrib-id contrib-id-type="orcid">https://orcid.org/0000-0001-9956-2385</contrib-id><name-alternatives><name name-style="eastern" xml:lang="ru"><surname>Слогоцкая</surname><given-names>Л. В.</given-names></name><name name-style="western" xml:lang="en"><surname>Slogotskaya</surname><given-names>L. V.</given-names></name></name-alternatives><bio xml:lang="ru"><p>Слогоцкая Людмила Владимировна, доктор медицинских наук, заведующая научно-клиническим отделом.</p><p>107014, Москва, ул. Стромынка, д. 10.</p></bio><bio xml:lang="en"><p>Ludmila V. Slogotskaya, Doctor of Medical Sciences, Head of Research Clinical Department.</p><p>10, Stromynka St., Moscow, 107014.</p></bio><email xlink:type="simple">lyu186@yandex.ru</email><xref ref-type="aff" rid="aff-1"/></contrib><contrib contrib-type="author" corresp="yes"><contrib-id contrib-id-type="orcid">https://orcid.org/0000-0003-4552-5022</contrib-id><name-alternatives><name name-style="eastern" xml:lang="ru"><surname>Богородская</surname><given-names>Е. М.</given-names></name><name name-style="western" xml:lang="en"><surname>Bogorodskaya</surname><given-names>E. M.</given-names></name></name-alternatives><bio xml:lang="ru"><p>Богородская Елена Михайловна, доктор медицинских наук, профессор, директор.</p><p>107014, Москва, ул. Стромынка, д. 10.</p></bio><bio xml:lang="en"><p>Elena M. Bogorodskaya, Doctor of Medical Sciences, Professor, Director.</p><p>10, Stromynka St., Moscow, 107014.</p></bio><email xlink:type="simple">el_bogorodskaya@mail.ru</email><xref ref-type="aff" rid="aff-1"/></contrib><contrib contrib-type="author" corresp="yes"><contrib-id contrib-id-type="orcid">https://orcid.org/0000-0002-4808-0658</contrib-id><name-alternatives><name name-style="eastern" xml:lang="ru"><surname>Шамуратова</surname><given-names>Л. Ф.</given-names></name><name name-style="western" xml:lang="en"><surname>Shamuratova</surname><given-names>L. F.</given-names></name></name-alternatives><bio xml:lang="ru"><p>Шамуратова Луиза Фазыловна, заведующая отделением фтизиопедиатрической помощи организационно-методического отдела.</p><p>107014, Москва, ул. Стромынка, д. 10.</p></bio><bio xml:lang="en"><p>Luiza F. Shamuratova, Head of Pediatric Phthisiologic Care Unit of Statistic and Reporting Department.</p><p>10, Stromynka St., Moscow, 107014.</p></bio><email xlink:type="simple">l.shamuratova@yandex.ru</email><xref ref-type="aff" rid="aff-2"/></contrib><contrib contrib-type="author" corresp="yes"><contrib-id contrib-id-type="orcid">https://orcid.org/0000-0003-1499-4934</contrib-id><name-alternatives><name name-style="eastern" xml:lang="ru"><surname>Севостьянова</surname><given-names>Т. А.</given-names></name><name name-style="western" xml:lang="en"><surname>Sevostyanova</surname><given-names>T. A.</given-names></name></name-alternatives><bio xml:lang="ru"><p>Севостьянова Татьяна Александровна, доктор медицинских наук, заведующая детским консультационно-диагностическим отделением.</p><p>107014, Москва, ул. Стромынка, д. 10.</p></bio><bio xml:lang="en"><p>Tatiana A. Sevostyanova, Doctor of Medical Sciences, Head of Pediatric Consulting Diagnostic Department.</p><p>10, Stromynka St., Moscow, 107014.</p></bio><email xlink:type="simple">sewata@yandex.ru</email><xref ref-type="aff" rid="aff-2"/></contrib></contrib-group><aff-alternatives id="aff-1"><aff xml:lang="ru"><institution>ГБУЗ «Московский городской научно-практический центр борьбы с туберкулезом Департамента здравоохранения города Москвы»; ФГБОУ ДПО «Российская медицинская академия непрерывного профессионального образования» МЗ РФ</institution><country>Россия</country></aff><aff xml:lang="en"><institution>Moscow Municipal Scientific Practical Center of Tuberculosis Control; Russian Medical Academy of On-going Professional Education</institution><country>Russian Federation</country></aff></aff-alternatives><aff-alternatives id="aff-2"><aff xml:lang="ru"><institution>ГБУЗ «Московский городской научно-практический центр борьбы с туберкулезом Департамента здравоохранения города Москвы»</institution><country>Россия</country></aff><aff xml:lang="en"><institution>Moscow Municipal Scientific Practical Center of Tuberculosis Control</institution><country>Russian Federation</country></aff></aff-alternatives><pub-date pub-type="collection"><year>2021</year></pub-date><pub-date pub-type="epub"><day>12</day><month>01</month><year>2022</year></pub-date><volume>99</volume><issue>12</issue><fpage>14</fpage><lpage>21</lpage><permissions><copyright-statement>Copyright &amp;#x00A9; Слогоцкая Л.В., Богородская Е.М., Шамуратова Л.Ф., Севостьянова Т.А., 2022</copyright-statement><copyright-year>2022</copyright-year><copyright-holder xml:lang="ru">Слогоцкая Л.В., Богородская Е.М., Шамуратова Л.Ф., Севостьянова Т.А.</copyright-holder><copyright-holder xml:lang="en">Slogotskaya L.V., Bogorodskaya E.M., Shamuratova L.F., Sevostyanova T.A.</copyright-holder><license xml:lang="ru" license-type="creative-commons-attribution" xlink:href="https://creativecommons.org/licenses/by/4.0/" xlink:type="simple"><license-p>Данная работа распространяется под лицензией Creative Commons Attribution 4.0.</license-p></license><license xml:lang="en" license-type="creative-commons-attribution" xlink:href="https://creativecommons.org/licenses/by/4.0/" xlink:type="simple"><license-p>This work is licensed under a Creative Commons Attribution 4.0 License.</license-p></license></permissions><self-uri xlink:href="https://www.tibl-journal.com/jour/article/view/1593">https://www.tibl-journal.com/jour/article/view/1593</self-uri><abstract><sec><title>Цель</title><p>Цель: оценка эффективности массового скрининга для выявления туберкулезной инфекции у детей в возрасте от 1 до 7 лет в разные периоды ‒ до и после начала использования кожной пробы с аллергеном туберкулезным рекомбинантным (АТР) в учреждениях первичной медико-санитарной помощи в качестве дополнительного метода диагностики.</p></sec><sec><title>Материалы и методы</title><p>Материалы и методы. Дизайн работы – сплошное наблюдательное проспективно-ретроспективное исследование. Взяты 2 разных периода: первый – 2014-2016 гг., когда скрининг туберкулезной инфекции проводили у всех детей от 1 до 17 лет (включительно) при помощи пробы Манту с 2 ТЕ ППД-Л в учреждениях первичной медико-санитарной помощи детскому населению, а затем детей с увеличением реакции направляли в противотуберкулезный диспансер, где при необходимости их обследовали при помощи кожной пробы с АТР; второй период ‒ 2018-2020 гг., когда детям 1-7 лет проводили пробу Манту и при подозрении на развитие туберкулезной инфекции ‒ кожную пробу с АТР как в учреждениях общей лечебной сети, так и в условиях противотуберкулезного учреждения. В первые 3 года обследовано 1 864 137, а во вторые 3 года – 2 078 800 детей в возрасте 1-7 лет.</p></sec><sec><title>Результаты</title><p>Результаты. Среди детей 1-7 лет, которым проводится двухэтапный скрининг (сначала пробой Манту, затем у лиц с положительной реакцией ‒ пробой с АТР), из направленных к фтизиатру только 10-12% подлежали диспансерному наблюдению. Таким образом, с внедрением нового приказа по скринингу туберкулезной инфекции у детей двумя пробами эта доля не изменилась по сравнению с предыдущими годами, когда скрининг проводился только одной пробой Манту. Причина, по которой почти 90% детей из тех, кто был направлен в ПТД, не подлежали диспансерному наблюдению, состоит в следующем: дети, у которых ранее уже был зафиксирован «вираж» туберкулиновых проб, наряду со всеми, опять проходят скрининг пробой Манту, несмотря на то что наблюдаются или наблюдались ранее в противотуберкулезном диспансере по поводу первичного инфицирования.</p></sec><sec><title>Рекомендации</title><p>Рекомендации:</p></sec></abstract><trans-abstract xml:lang="en"><sec><title>The objective</title><p>The objective: to evaluate effectiveness of mass screening for tuberculosis infection in children aged 1 to 7 years in different periods – before and after the use of tuberculosis recombinant allergen skin test (TRA) in primary health care as an additional diagnostic method.</p></sec><sec><title>Subjects and Methods</title><p>Subjects and Methods. The study was designed as continuous observational prospective-retrospective study. Two different periods were assessed: the first one was 2014-2016 when screening for tuberculosis infection was performed in all children from 1 to 17 years (inclusive) using Mantoux test with 2 TU PPD-L in pediatric primary health care, and then children suspected to have a positive reaction were referred to TB dispensary where they were examined with a skin test with TRA if necessary. The second period was from 2018 to 2020 when children of 1-7 years old were given Mantoux test and if tuberculosis infection was suspected, a skin test with TRA was done both in primary health care network and TB units. In the first 3 years, 1,864,137 children were examined and in the second 3 years, 2,078,800 children from 1 to 7 years old were examined.</p></sec><sec><title>Results</title><p>Results. Among children of 1-7 years old who were screened by two stages (initial Mantoux test, and then in those who had a positive reaction, the TRA test was used), only 10-12% of those referred to a phthisiologist were subject to dispensary follow-up. Thus, with the implementation of the new edict on screening for tuberculosis infection in children with two tests, this proportion has not changed compared to previous years, when screening was carried out only with one Mantoux test. The reason why almost 90% of the children who were referred to TB Dispensary were not subject to dispensary follow-up is the following: children who have had previous conversion of tuberculin tests, along with everyone else are again screened with Mantoux test despite being previously followed up by TB dispensary due to the primary infection.</p></sec><sec><title>Recommendations</title><p>Recommendations:</p></sec></trans-abstract><kwd-group xml:lang="ru"><kwd>дети</kwd><kwd>туберкулинодиагностика</kwd><kwd>проба с АТР (диаскинтест)</kwd><kwd>выявление туберкулезной инфекции</kwd></kwd-group><kwd-group xml:lang="en"><kwd>children</kwd><kwd>tuberculin diagnostics</kwd><kwd>TRA test (diakintest)</kwd><kwd>detection of tuberculosis infection</kwd></kwd-group></article-meta></front><back><ref-list><title>References</title><ref id="cit1"><label>1</label><citation-alternatives><mixed-citation xml:lang="ru">Киселев В. И., Барановский П. М., Пупышев С. А. и др. Новый кожный тест для диагностики туберкулеза на основе рекомбинантного белка ESAT-CFP // Молекулярная медицина. – 2008. – № 4. – C. 4-6.</mixed-citation><mixed-citation xml:lang="en">Kiselev V.I., Baranovskiy P.M., Pupyshev S.А. et al. The new skin test for tuberculosis diagnostics based on recombinant protein of ESAT-CFP. Molekulyarnaya Meditsina, 2008, no. 4, pp. 4-6. (In Russ.)</mixed-citation></citation-alternatives></ref><ref id="cit2"><label>2</label><citation-alternatives><mixed-citation xml:lang="ru">Литвинов В. И. Иммуноморфология и иммунологическое значение повышенной чувствительности замедленного типа при туберкулезе: дис. … д-ра мед. наук. – М., 1974. – 387 c.</mixed-citation><mixed-citation xml:lang="en">Litvinov V.I. Immunomorfologiya i immunologicheskoye znacheniye povyshennoy chuvstvitelnosti zamedlennogo tipa pri tuberkuleze. Diss. dokt. med. nauk. [Immunomorphology and immunological significance of delayed-type hypersensitivity in tuberculosis. Doct. Diss.]. Moscow, 1974, 387 p.</mixed-citation></citation-alternatives></ref><ref id="cit3"><label>3</label><citation-alternatives><mixed-citation xml:lang="ru">Литвинов В. И., Слогоцкая Л. В., Сельцовский П. П. и др. Новый кожный тест для диагностики туберкулезной инфекции // Российский медицинский журнал. – 2009. – № 1. – С. 52-56.</mixed-citation><mixed-citation xml:lang="en">Litvinov V.I., Slogotskaya L.V., Seltsovskiy P.P. et al. New skin test for tuberculous infection diagnostics. Rossiyskiy Meditsinskiy Journal, 2009, no. 1, pp. 52-56. (In Russ.)</mixed-citation></citation-alternatives></ref><ref id="cit4"><label>4</label><citation-alternatives><mixed-citation xml:lang="ru">Приказ Минздрава России от 29.12.2014 г. № 951. «Об утверждении методических рекомендаций по совершенствованию диагностики и лечения туберкулеза органов дыхания» / М-во здравоохранения России. – М., 2014. – URL: https://www.garant.ru/products/ipo/prime/doc/70749840/.</mixed-citation><mixed-citation xml:lang="en">Edict no. 951 by the Russian Ministry of Health as of December 29, 2014. On Approval of Clinical Guidelines on Improvement of Diagnostics and Treatment of Respiratory Tuberculosis. M-vo Zdravookhraneniya Rossii Publ., Moscow, 2014. (In Russ.) Available: https://www.garant.ru/products/ipo/prime/doc/70749840/.</mixed-citation></citation-alternatives></ref><ref id="cit5"><label>5</label><citation-alternatives><mixed-citation xml:lang="ru">Приказ Минздрава России от 21.03.2017 г. № 124н «Об утверждении порядка и сроков проведения профилактических медицинских осмотров граждан в целях выявления туберкулеза».</mixed-citation><mixed-citation xml:lang="en">Edict no. 124n as of March 21, 2017 by the Russian Ministry of Health On the Approval of Procedure and Time Frames of Preventive Mass Screening of Population for Tuberculosis. (In Russ.)</mixed-citation></citation-alternatives></ref><ref id="cit6"><label>6</label><citation-alternatives><mixed-citation xml:lang="ru">Приказ Минздрава РФ от 13.03.2019 № 127Н «Об утверждении порядка диспансерного наблюдения за больными туберкулезом, лицами, находящимися или находившимися в контакте с источником туберкулеза, а также лицами с подозрением на туберкулез и излеченными от туберкулеза и признании утратившими силу пунктов 16-17 порядка оказания медицинской помощи больным туберкулезом, утвержденного приказом Министерства здравоохранения Российской Федерации от 15 ноября 2012 г. № 932н.</mixed-citation><mixed-citation xml:lang="en">Edict no. 127N by the Russian Ministry of Health as of March 13, 2019 On Approval of the Procedure of Dispensary Follow-up over Tuberculosis Patients, Those Exposed to Tuberculosis Infection, and Persons Suspected to Have Tuberculosis and Cured of Tuberculosis and the Recognition of Clauses 16-17 of the Procedure of Medical Care for Tuberculosis Patients, Approved by Edict no. 932n of the Russian Ministry of Health as of November 15, 2012, as no longer valid. (In Russ.)</mixed-citation></citation-alternatives></ref><ref id="cit7"><label>7</label><citation-alternatives><mixed-citation xml:lang="ru">Приказ Минздравсоцразвития России от 29.10.2009 г. № 855. «О внесении изменения в приложение № 4 к Приказу Минздрава России от 21 марта 2003 г. № 109».</mixed-citation><mixed-citation xml:lang="en">Edict no. 855 as of October 29, 2009 by the Russian Ministry of Health and Social Development. On Changes to Appendix no. 4 to Edict no. 109 as of March 21, 2003 by the Russian Ministry of Health. (In Russ.)</mixed-citation></citation-alternatives></ref><ref id="cit8"><label>8</label><citation-alternatives><mixed-citation xml:lang="ru">Слогоцкая Л. В., Богородская Е. М., Шамуратова Л. Ф., Севостьянова Т. А. Эффективность скрининга туберкулезной инфекции у детей и подростков в г. Москве в 2019 г. на основе нового алгоритма применения внутрикожной пробы с аллергеном туберкулезным рекомбинантным (ESAT-6/CFP-10) // Туб. и болезни легких. – 2021. – Т. 99, № 1. – С. 15-25.</mixed-citation><mixed-citation xml:lang="en">Slogotskaya L.V., Bogorodskaya E.M., Shamuratova L.F., Sevostyanova T.А. Efficiency of screening for tuberculosis infection in children and adolescents in Moscow in 2019 based on the new procedure for using the intradermal test with tuberculosis recombinant allergen (ESAT-6/CFP-10). Tuberculosis and Lung Diseases, 2021, vol. 99, no. 1, pp. 15-25. (In Russ.)</mixed-citation></citation-alternatives></ref><ref id="cit9"><label>9</label><citation-alternatives><mixed-citation xml:lang="ru">Affronti L., Lind A., Ouchterlony O. et al. An evaluation of the polyacrylamide gel electrophoresis fractionation method for the production of Mycobacterium tuberculosis skin test preparations. I. Production, physiochemical characterization and serological analyses // J. Biol. – 1986. – Vol. 26. – P. 1-18.</mixed-citation><mixed-citation xml:lang="en">Affronti L., Lind A., Ouchterlony O. et al. An evaluation of the polyacrylamide gel electrophoresis fractionation method for the production of Mycobacterium tuberculosis skin test preparations. I. Production, physiochemical characterization and serological analyses. J. Biol., 1986, vol. 26, pp. 1-18.</mixed-citation></citation-alternatives></ref><ref id="cit10"><label>10</label><citation-alternatives><mixed-citation xml:lang="ru">Boussiotis V., Tsai E., Yunis E. et al. IL-10-producing T cells suppress immune responses in anergic tuberculosis patients // J. Clin. Invest. ‒ 2000. ‒ Vol. 105, № 9. – P. 1317-1325.</mixed-citation><mixed-citation xml:lang="en">Boussiotis V., Tsai E., Yunis E. et al. IL-10-producing T cells suppress immune responses in anergic tuberculosis patients. J. Clin. Invest., 2000, vol. 105, no. 9, pp. 1317-1325.</mixed-citation></citation-alternatives></ref><ref id="cit11"><label>11</label><citation-alternatives><mixed-citation xml:lang="ru">Cobat A., Gallant C., Simkin L., Black G., Kim S., Hughes J. et al. Two loci control tuberculin skin test reactivity in an area hyperendemic for tuberculosis // J. Exp. Med. ‒ 2009. ‒ Vol. 206, № 12. ‒ Р. 2583-2591. DOI: 10.1084 / jem.20090892.</mixed-citation><mixed-citation xml:lang="en">Cobat A., Gallant C., Simkin L., Black G., Kim S., Hughes J. et al. Two loci control tuberculin skin test reactivity in an area hyperendemic for tuberculosis. J. Exp. Med., 2009, vol. 206, no. 12, pp. 2583-2591. doi: 10.1084 / jem.20090892.</mixed-citation></citation-alternatives></ref><ref id="cit12"><label>12</label><citation-alternatives><mixed-citation xml:lang="ru">Cole S., Brosch R., Parkhill J. et al. Deciphering the biology of Mycobacterium tuberculosis from the complete genome sequence // Nature. – 1998. – Vol. 393. – P. 537-544.</mixed-citation><mixed-citation xml:lang="en">Cole S., Brosch R., Parkhill J. et al. Deciphering the biology of Mycobacterium tuberculosis from the complete genome sequence. Nature, 1998, vol. 393, pp. 537-544.</mixed-citation></citation-alternatives></ref><ref id="cit13"><label>13</label><citation-alternatives><mixed-citation xml:lang="ru">Dillon D., Alderson М., Day Н. et al. Molecular and immunological character izationof Mycobacterium tuberculosis CFP-10, an immunodiagnostic antigen missing in Mycobacterium bovis BCG // J. Clin. Microbiol. ‒ 2000. ‒ Vol. 38. ‒ P. 3285-3290.</mixed-citation><mixed-citation xml:lang="en">Dillon D., Alderson М., Day Н. et al. Molecular and immunological characterization of Mycobacterium tuberculosis CFP-10, an immunodiagnostic antigen missing in Mycobacterium bovis BCG. J. Clin. Microbiol., 2000, vol. 38, pp. 3285-3290.</mixed-citation></citation-alternatives></ref><ref id="cit14"><label>14</label><citation-alternatives><mixed-citation xml:lang="ru">Mahairas G., Sabo P., Hickey M. et al. Molecular analysis of genetic differences between Mycobacterium bovis BCG and virulent M. bovis // J. Bacteriol. – 1996. – Vol. 178. – P. 1274-1282.</mixed-citation><mixed-citation xml:lang="en">Mahairas G., Sabo P., Hickey M. et al. Molecular analysis of genetic differences between Mycobacterium bovis BCG and virulent M. bovis. J. Bacteriol., 1996, vol. 178, pp. 1274-1282.</mixed-citation></citation-alternatives></ref><ref id="cit15"><label>15</label><citation-alternatives><mixed-citation xml:lang="ru">Marais B., Gie R., Schaaf H., Hesseling A., Obihara C., Starke J. et al. The natural history of childhood intra-thoracic tuberculosis ‒ a critical review of literature from the pre-chemotherapy era // Int. J. Tuberc. Lung Dis. ‒ 2004. ‒ № 8. ‒ Р. 392-340.</mixed-citation><mixed-citation xml:lang="en">Marais B., Gie R., Schaaf H., Hesseling A., Obihara C., Starke J. et al. The natural history of childhood intra-thoracic tuberculosis ‒ a critical review of literature from the pre-chemotherapy era. Int. J. Tuberc. Lung Dis., 2004, no. 8, pp. 392-340.</mixed-citation></citation-alternatives></ref><ref id="cit16"><label>16</label><citation-alternatives><mixed-citation xml:lang="ru">Pai M. Innovations in tuberculosis diagnostics: progress and translational challenges // EBioMedicine. – 2015. – Vol. 2, № 3. – P. 182-183. doi: 10.1016/j.ebiom.2015.01.018.</mixed-citation><mixed-citation xml:lang="en">Pai M. Innovations in tuberculosis diagnostics: progress and translational challenges. EBioMedicine, 2015, vol. 2, no. 3, pp. 182-183. doi: 10.1016/j.ebiom.2015.01.018.</mixed-citation></citation-alternatives></ref><ref id="cit17"><label>17</label><citation-alternatives><mixed-citation xml:lang="ru">Palmer C., Edwards L. Tuberculin test in retrospect and prospect // Arch. Environ. Health. – 1967. – Vol. 15, № 6. – P. 792-808.</mixed-citation><mixed-citation xml:lang="en">Palmer C., Edwards L. Tuberculin test in retrospect and prospect. Arch. Environ. Health, 1967, vol. 15, no. 6, pp. 792-808.</mixed-citation></citation-alternatives></ref><ref id="cit18"><label>18</label><citation-alternatives><mixed-citation xml:lang="ru">Simmons J., Stein C., Chetan S., Campo M., Alter G., Fortune S. et al. Immunological mechanisms of human resistance to persistent Mycobacterium tuberculosis infection // Nat. Rev. Immunol. ‒ 2018. ‒ Vol. 18, № 9. ‒ Р. 575-589. doi:10.1038/ s41577-018-0025-3.</mixed-citation><mixed-citation xml:lang="en">Simmons J., Stein C., Chetan S., Campo M., Alter G., Fortune S. et al. Immunological mechanisms of human resistance to persistent Mycobacterium tuberculosis infection. Nat. Rev. Immunol., 2018, vol. 18, no. 9, pp. 575-589. doi:10.1038/ s41577-018-0025-3.</mixed-citation></citation-alternatives></ref><ref id="cit19"><label>19</label><citation-alternatives><mixed-citation xml:lang="ru">Slogotskaya L., Bogorodskaya E., Ivanova D., Sevostyanova T. Comparative sensitivity of the test with tuberculosis recombinant allergen, containing ESAT6-CFP10 protein, and Mantoux test with 2 TU PPD-L in newly diagnosed tuberculosis children and adolescents in Moscow // Plos ONE. – 2018. ‒ Vol. 13, № 12. ‒ Р. e0208705.</mixed-citation><mixed-citation xml:lang="en">Slogotskaya L., Bogorodskaya E., Ivanova D., Sevostyanova T. Comparative sensitivity of the test with tuberculosis recombinant allergen, containing ESAT6-CFP10 protein, and Mantoux test with 2 TU PPD-L in newly diagnosed tuberculosis children and adolescents in Moscow. Plos ONE, 2018, vol. 13, no. 12, pp. e0208705.</mixed-citation></citation-alternatives></ref><ref id="cit20"><label>20</label><citation-alternatives><mixed-citation xml:lang="ru">Thye T., Browne E., Chinbuah M. et al. IL10 Haplotype associated with tuberculin skin test response but not with pulmonary TB // PLoSONE. – 2009. – Vol. 4, № 5. – Р. e5420.</mixed-citation><mixed-citation xml:lang="en">Thye T., Browne E., Chinbuah M. et al. IL10 Haplotype associated with tuberculin skin test response but not with pulmonary TB. PLoSONE, 2009, vol. 4, no. 5, pp. e5420.</mixed-citation></citation-alternatives></ref><ref id="cit21"><label>21</label><citation-alternatives><mixed-citation xml:lang="ru">Vukmanovic-Stejic M., Reed J., Lacy K. et al. Mantoux Test as a model for a secondary immune response in humans // Immunol. Lett. – 2006. – Vol. 107, № 2. – P. 93-110.</mixed-citation><mixed-citation xml:lang="en">Vukmanovic-Stejic M., Reed J., Lacy K. et al. Mantoux Test as a model for a secondary immune response in humans. Immunol. Lett., 2006, vol. 107, no. 2, pp. 93-110.</mixed-citation></citation-alternatives></ref><ref id="cit22"><label>22</label><citation-alternatives><mixed-citation xml:lang="ru">WHO. Consensus meeting report: development of a Target Product Profile (TPP) and a framework for evaluation for a test for predicting progression from tuberculosis infection to active disease / World Health Organization. ‒ Geneva, 2017 (WHO/HTM/TB/2017.18). Licence: CC BY-NC-SA3.0 IGO.</mixed-citation><mixed-citation xml:lang="en">WHO, Consensus meeting report: development of a Target Product Profile (TPP) and a framework for evaluation for a test for predicting progression from tuberculosis infection to active disease / World Health Organization. Geneva, 2017 (WHO/HTM/TB/2017.18). Licence: CC BY-NC-SA3.0 IGO.</mixed-citation></citation-alternatives></ref><ref id="cit23"><label>23</label><citation-alternatives><mixed-citation xml:lang="ru">WHO. Global tuberculosis report. 2018.</mixed-citation><mixed-citation xml:lang="en">WHO, Global tuberculosis report. 2018.</mixed-citation></citation-alternatives></ref><ref id="cit24"><label>24</label><citation-alternatives><mixed-citation xml:lang="ru">WHO. Implementing the end TB strategy: the essentials / World Health Organization. Geneva, 2015 (WHO/HTM/TB/2015.31; http://www.who. int/tb/publications/ 2015/end_tb_essential.pdf?ua=1, accessed 18 July 2017).</mixed-citation><mixed-citation xml:lang="en">WHO, Implementing the end TB strategy: the essentials. World Health Organization. Geneva, 2015 (WHO/HTM/TB/2015.31, http://www.who. int/tb/publications/ 2015/end_tb_essential.pdf?ua=1, Accessed 18 July 2017).</mixed-citation></citation-alternatives></ref><ref id="cit25"><label>25</label><citation-alternatives><mixed-citation xml:lang="ru">WHO. Latent tuberculosis infection: updated and consolidated guidelines for programmatic management / World Health Organization. ‒ Geneva, 2018.</mixed-citation><mixed-citation xml:lang="en">WHO, Latent tuberculosis infection: updated and consolidated guidelines for programmatic management. World Health Organization. Geneva, 2018.</mixed-citation></citation-alternatives></ref><ref id="cit26"><label>26</label><citation-alternatives><mixed-citation xml:lang="ru">WHO. Report on BCG vaccine use for protection against mycobacterial infections including tuberculosis, leprosy, and other nontuberculous mycobacteria (NTM) infections Prepared by the SAGE Working Group on BCG Vaccines and WHO Secretariat 22. September 2017.</mixed-citation><mixed-citation xml:lang="en">WHO, Report on BCG vaccine use for protection against mycobacterial infections including tuberculosis, leprosy, and other nontuberculous mycobacteria (NTM) infections Prepared by the SAGE Working Group on BCG Vaccines and WHO Secretariat 22. September 2017.</mixed-citation></citation-alternatives></ref></ref-list><fn-group><fn fn-type="conflict"><p>The authors declare that there are no conflicts of interest present.</p></fn></fn-group></back></article>
